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months pre- and post-index periods. Patients with diabetic peripheral neuropathic pain 
(DPNP) or depression in the 12 months pre-index period were excluded. Each patient 
was classiﬁed in the duloxetine or prebagalin cohort based on the initial agent. Pre-
bagalin cohort was constructed via propensity scoring controlling for differences in 
demographics, pre-index clinical and economic characteristics, and pre-index treat-
ment patterns. Medication compliance (i.e. medication possession ratio (MPR) and 
proportion of patients with MPRq80%) and health care costs over the 12 months 
post-index period were examined between cohorts. RESULTS: Both the duloxetine (n 
 3711) and pregabalin (n  4111) cohorts had the mean age around 50 years. Many 
duloxetine and pregabalin patients had neuropathic pain other than DPNP (69.1% 
vs. 69.1%), low back pain (61.9% vs. 62.1%), cardiovascular disease (55.1% vs. 
55.1%), hypertension (44.9% vs. 45.0%), and headache (36.0% vs. 35.3%), and used 
opioids (75% vs. 86%). Controlling for demographics, pre-index clinical and eco-
nomic characteristics, and prior medication history, duloxetine patients had signiﬁ-
cantly higher MPR (0.66 vs. 0.50, p  0.05), higher proportion of patients with 
MPRq80% (47% vs. 26%, p  0.05), and signiﬁcantly lower total health care costs 
($19,378 vs. $27,045, p  0.05) over the 12 months follow-up period than pregabalin 
patients. CONCLUSIONS: Fibromyalgia patients treated with duloxetine had signiﬁ-
cantly higher medication compliance, but signiﬁcantly lower direct health care costs 
than those on pregabalin.
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OBJECTIVES: To describe the adherence for different treatment regimens of oral 
bisphosphonates (oBP) in osteoporosis patients in Germany. METHODS: Analyses 
used IMS® Disease Analyser database (contains representative information on 
approximately 11 million patients from ofﬁce-based physicians). Osteoporosis patients 
with a history of malignant diseases, any anticancer or cytostatic hormone prescrip-
tions, Paget’s disease or AIDS were excluded. Eligible osteoporosis patients had data 
available at least 1-year before and after starting oBP treatment between Dec 2004 
and Nov 2007. Compliance was measured as Medical Possession Ratio (MPR); 
deﬁned as the ratio of prescribed to assumed number of therapy units. MPR  80% 
assumed compliance. MPR was calculated for patients on therapy for a maximum of 
2 years. RESULTS: Data from 4,738 patients were analyzed: 4147 (87.5%) women, 
4130 (87.2%) older than 60 years. A total of 177 (3.7%) received daily, 4367 (92.2%) 
weekly and 194 (4.1%) monthly oBP treatment. The mean MPR was 0.66 (daily), 
0.83 (weekly) and 0.84 (monthly) in the oBP treatment period. In total, only 51% of 
patients had an MPR  80%. Overall, 72% patients discontinued/switched oBP 
regimen during the ﬁrst year: 90.4% (daily), 71.6% (weekly) and 70.6% (monthly). 
CONCLUSIONS: The majority of patients were receiving weekly oBP therapy. Com-
pliance varied for the different treatment regimens, but was particularly poor in 
patients receiving daily oBP treatment. In addition, a high proportion of patients dis-
continued/switched oBP regimens during the ﬁrst year. This study provides further 
evidence of poor adherence in patients with osteoporosis receiving oBP therapy.
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OBJECTIVES: To reduce and validate the ADEOS questionnaire, an instrument spe-
ciﬁcally developed to evaluate treatment adherence by women with post-menopausal 
osteoporosis. METHODS: The ADEOS questionnaire has been developed with clini-
cians and patients. Before item reduction, it included 45 items covering 5 distinct 
themes related to adherence (personal characteristics, beliefs, perceptions, behaviour 
and information received). It was included for ﬁnalisation and validation in a cross-
sectional observational study in French general practitioners. The study sample was 
randomly divided into 2 subsamples: one for item selection, one for validation. The 
item selection procedure was performed according to the association of the items with 
a generic measure of compliance, the Morisky Medication Adherence Scale (MMAS). 
The validity of the score derived from these items was scrutinised by assessing its 
correlation with MMAS score. Its ability to separate compliant patients from non 
compliant patients according to MMAS was studied using area under receiver-operat-
ing characteristic curve (AUC). RESULTS: Five hundred sixty osteoporotic women 
were included, of whom 348 (62%) returned the ADEOS questionnaire. Patients who 
did not return the questionnaire were comparable to those who did in terms of demo-
graphics and medical parameters. The questionnaire quality of completion was very 
good, conﬁrming its good acceptability. Twelve items of the questionnaire showed a 
statistically signiﬁcant relationship (p  0.05) with the MMAS in the “item selection 
sample” (N  200) and were retained to derive the ADEOS score. In the “validation 
sample” (N  148), the ADEOS score was noticeably correlated with MMAS score 
(Spearman correlation coefﬁcient: 0.58) and showed good discriminant validity 
according to MMAS (AUC: 0.84). CONCLUSIONS: The 12-item ADEOS question-
naire is a short validated instrument speciﬁc to osteoporosis, whose score can easily 
be calculated by hand. Therefore, it might be particularly useful in daily practice to 
detect patients at risk of being poorly adherent to their osteoporosis treatment.
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OBJECTIVES: Recent anti-osteoporotic treatments are characterised by monthly or 
even yearly administration. These treatments may challenge the prescription of daily-
administered drugs. The objective of this qualitative research was to explore patients’ 
perception as well as clinicians’ views on the frequency of anti-osteoporotic treatment 
administration. METHODS: A health psychologist carried out face-to-face interviews 
with six patients treated on a daily basis and six patients treated with a monthly-
administered drug. The patients’ perception, behaviour and expectations regarding 
anti-osteoporotic treatment were assessed. Clinicians who recruited the patients, com-
prising a general practitioner and specialists, were also interviewed. Information on 
factors driving their treatment choice decision and on the importance of patients’ 
feedback and perception in their decision was collected. RESULTS: Patients perceived 
osteoporosis as a sign of premature ageing and a disease of secondary importance. 
They reported that a daily administration was not a problem per se if it did not modify 
their lifestyle. They raised concerns about lower frequency of drug administration that 
clinicians did not: the difﬁculty of remembering to take the treatment; the worry about 
the treatment being too concentrated, with the thought of a possible irregular efﬁcacy 
of the drug over the time and a harmful effect. They did not feel involved in the choice 
of treatment. Clinicians believed monthly administration to be more convenient than 
daily administration. They declared choosing the treatment according to the patient’s 
characteristics, in particular concomitant diseases, lifestyle, and dosing preference. 
CONCLUSIONS: Discrepancies exist between clinicians’ perception and reality for 
patients regarding anti-osteoporotic treatment. Consequently, possible patient-
reported outcomes approaches to improve treatment-decision would consist in 1) 
educating patients on osteoporosis, and clinicians on their patients’ perception and 
expectations, and 2) promoting shared decision-making. This is likely to contribute 
to a better persistence of the patients with regard to their treatment.
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OBJECTIVES: To compare the predictive power post hoc of skin signs and physical 
function in improvement of health state utility scores in a population with active 
psoriatic arthritis (PsA). METHODS: A 12-week randomized double-blind study fol-
lowed by a 12-week open-label extension; subjects received etanercept 50 mg BIW or 
50 mg QW during the double-blind period followed by 50 mg QW during the open-
label period. Eligibility criteria included: age 18 y; stable, moderate-to-severe plaque 
psoriasis with q2 swollen/painful joints. PASI for psoriasis signs, HAQ for physical 
function, and EQ-5D were measured at baseline, Weeks 12 and 24. Logistic regression 
was used to predict the minimally clinically meaningful change in EQ-5D of at least 
0.05 (0–1.0 scale). Meaningful changes from baseline as predictors: HAQ  0.375, 
0.5; PASI  50%, 75%. RESULTS: At baseline, subjects (n  752) had a mean age 
47 y, were 63% male, and 89% white. Mean number of tender joints 19.2, and 
swollen joints 12.5. Mean durations of psoriasis and psoriatic arthritis 19 and 7 
years, respectively. Baseline scores were not signiﬁcantly different between the 2 
groups; pooled baseline (mean o s.d.) PASI  19.43 o 10.28, HAQ  0.91 o 0.69, and 
EQ-5D  0.48 o 0.32. Only PASI change from baseline at Week 12 differentiated 
treatment groups. Pooled reductions from baseline to Week 24 (LOCF) were: PASI  
75.9%, HAQ  52.0%. Proportion achieving EQ-5D (q0.05)  74.6%. HAQ changes 
from baseline were stronger predictors of pre-determined changes in EQ-5D utility 
scores than PASI changes, with HAQ change q0.375 at Week 24 being the strongest 
single change predictor (OR  4.36 (2.01–9.44)). Higher baseline HAQ scores reduced 
the odds 0.12 (0.07–0.20), and 0.19 (0.11–0.31) for minimally meaningful health 
status improvements at Weeks 12 and 24, respectively. CONCLUSIONS: Patients 
with less advanced PsA could have better odds of meaningful improvement in health 
status when treated to reduce both skin and joint morbidity.
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OBJECTIVES: To examine the relationship between disease speciﬁc-measure, Health 
Assessment Questionnaire (HAQ) disability index (DI) and the preference-based mea-
sures, Short Form-6D (SF-6D) and the EuroQoL (EQ-5D) in patients with rheumatoid 
arthritis(RA) and psoriatic arthritis (PsA). METHODS: Five hundred and four patients 
attending a rheumatology outpatient clinic with RA and PsA completed the HAQ, 
Short Form-36 and the EQ-5D before starting biologic therapy and 12 months after. 
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The SF-36 was converted into a utility using the preference-based SF-6D. Clinical 
outcomes such European League Against Arthritis (EULAR) Disease Activity Score 
(DAS), joint counts and laboratory measures were also recorded. We calculated single 
index utility scores from the preference-based instruments using UK population norms. 
We used regression analysis and correlation coefﬁcients to compare relationships 
between the Quality of Life (QoL) outcomes and also the clinical outcomes and 
between observed and mapped utility scores. RESULTS: There was a signiﬁcant dif-
ference between the mapped and observed EQ-5D and SF-6D. Overall the mapped 
utilities produced higher values than the actual observed scores. The mean change in 
utility due to treatment is greater with the EQ-5D for both mapped and observed 
utilities. A greater change was seen in the PsA group. CONCLUSIONS: We present 
the different results produced when using mapped utility scores and directly obtained 
scores. We have highlighted the problems associated with deriving utilities from non 
preference-based instruments and the differences in utilities when calculated using 
different measures. While these methods do offer alternatives for researchers when 
performing cost utility analysis they remain suboptimal to the direct method.
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OBJECTIVES: To test the comprehension of the FMBA© in France, Germany and 
Spain. METHODS: The FMBA© was tested to assess ease of comprehension, cultural 
equivalence, clarity, wording and acceptability of the structure and content to patients. 
The test version contained 79 items grouped into 7 sections measuring burden of 
ﬁbromyalgia on patients’ daily lives, developed simultaneously in French, German, 
Spanish and UK English. These sections evaluate Pain, Physical Impact, Impact on 
daily activities, Social Impact, Work Impact, Psychological Impact, Relationship to 
doctors and treatment, and One general item. Sixteen ﬁbromyalgia patients were 
interviewed in France, Germany and Spain. UK comprehension tests are currently 
under way. Based on test results and deliberation with ﬁbromyalgia experts, changes 
were made to the French, German, Spanish and UK English versions of the question-
naire during an international harmonisation meeting. RESULTS: Patients’ overall 
comprehension of the questionnaire was good. The comprehension tests identiﬁed 
problematic items, and suggestions for deletions or rewording. Seventeen items were 
deleted for reasons such as; lack of conceptual clarity e.g. “I have pain that changes 
from one moment to the next” not clear between location and intensity; items con-
sidered conceptually too close e.g. “I get tired for no reason” deleted because too close 
to “I lack energy” and “I get tired easily”; and wording too strong” e.g. “I feel handi-
capped”. The answer choices were also modiﬁed to ensure cultural acceptance. The 
pilot version of the FMBA© contains 62 items divided into 7 sections. CONCLU-
SIONS: The FMBA© is a questionnaire that assesses the functional impact and burden 
of ﬁbromyalgia on patients’ daily lives. The FMBA© will allow the consequences of 
FM on patients to be more widely recognised. A validation study is to be undertaken 
to validate psychometric properties and scoring of the questionnaire.
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OBJECTIVES: To develop a European screening tool to help primary care physicians 
(PCPs) identify ﬁbromyalgia (FM) patients in general practice. METHODS: A Euro-
pean multidisciplinary expert group was set up to provide clinical expertise and iden-
tify key issues around FM detection. A literature review and focus groups conducted 
with French (FR), German (DE) and English (UK) clinicians provided an overview of 
the knowledge in FM and of clinicians’ awareness and experience. Psychologists then 
performed face-to-face exploratory interviews with FM patients (FR, DE and UK, n 
 29) to understand their attitudes and perceptions of the disease. Based on the ﬁnd-
ings, items were simultaneously generated in FR, UK and DE. The resulting tool was 
comprehension tested with FM-diagnosed or -suspected patients (n  3 and n  2 in 
each country, respectively), and modiﬁed based on results. Its acceptability and appli-
cability was then assessed in real-life conditions in general practice. RESULTS: The 
tool content deﬁned using literature review, health professional and patient input had 
high consistency regardless of the source from which it was extracted. Factors found 
that may contribute to the early detection of FM included elements of FM deﬁnition, 
patient characteristics, personal and medical history, quality of life, attitude and per-
sonality, associated symptoms and inﬂuencing factors. The resulting pilot version of 
the FM screening tool includes 14 questions assessing patients’ pain, fatigue, associ-
ated symptoms, impact on patients’ everyday life, personal history, and attitudes 
towards their symptoms. Face validity and feasibility have been conﬁrmed by PCPs 
and patients when administered in general practice. CONCLUSIONS: In addition to 
the symptomatic picture, FM detection requires the assessment of multiple factors 
including patient past history and characteristics, impact of FM on patients’ daily life, 
and situations/factors affecting patients’ condition. By capturing each of these factors, 
the European FM screening tool will help PCPs identify potential FM patients. Quan-
titative validation of the tool is underway.
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OBJECTIVES: Health related quality of life (HRQoL) is an important issue to evaluate 
outcomes after health interventions. The aim of this study was to study construct 
validity and responsiveness of the OsteoArthritis of Hip and Knee Quality of Life 
questionnaire (OAKHQOL), a disease-speciﬁc HRQoL for osteoarthritis of the lower 
limb. METHODS: OAKHQOL is a self administered questionnaire and has 43 items 
and ﬁve dimensions: physical activities (16), pain (4), mental health (13), social 
support (4) and social functioning (3). There are 3 independent items about relation-
ships, sexual activities and professional life. The score range from 0 (worst) to 100 
(best health). Patients were recruited patients from the waiting list to undergo joint 
replacement. The internal consistency was measured by Cronbach´s alpha (771 
patients). The test-retest reliability (413 stable patients who fulﬁlled the questionnaire 
two times) was measured by Intraclass correlation coefﬁcient (ICC). The responsive-
ness was evaluated by means of standardized effect size (SES) and standardized 
response mean (SRM) six months post surgical replacement. RESULTS: Cronbach´s 
alpha were all higher than 0.8 but in social activities dimension (0.64). Regarding 
test-retest reliability the ICCs were higher than 0.75 but in the social activities (0.4) 
and social support (0.4) dimensions. Finally, responsiveness parameters were: physical 
dimension (SES  1.26; SRM  0.89); pain (SES  1.37; SRM  0.94); mental health 
(SES  0.65; SRM  0.56). CONCLUSIONS: These results support the validity and 
responsiveness of the Spanish version of the OAKHQOL a disease speciﬁc HRQoL 
questionnaire to be used in patients with osteoarthritis of the lower limb and surgical 
management.
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OBJECTIVES: Development of validated patient-reported outcome (PRO) measures 
has the potential to positively impact scientiﬁc research and patient management. To 
date, the speciﬁc issues and symptoms most relevant to DM1 patients’ health related 
quality-of-life (HRQOL) have not been systematically assessed. Our goal is to identify 
those aspects of HRQOL that are most important to patients with DM1, a neuromus-
cular condition with multisystemic organ dysfunction. METHODS: We conducted 
in-depth individual patient interviews with twenty genetically conﬁrmed, adult, DM1 
patients representing varied levels of disability. Each interview focused on identifying 
the DM1 issues that have the greatest impact on patient HRQOL. Each interview was 
recorded, transcribed, coded, and analyzed using a qualitative framework technique, 
triangulation, and three investigator consensus approach. RESULTS: A total of 1175 
direct quotes were coded resulting in 223 like themes. These themes were subsequently 
categorized into 7 subdomains representing physical, mental, and social aspects of 
DM1 HRQOL. A disease-speciﬁc HRQOL conceptual model was created for DM1 
representing the most relevant symptomatic and psychosocial issues in this population. 
Categories in this model included: 1) mobility and ambulation/ ﬁne motor and upper 
extremity dysfunction; 2) emotional distress; 3) cognitive impairment; 4) social role 
limitations; 5) social role dissatisfaction; 6) activity impairment; and, 7) DM1-speciﬁc 
symptoms of: sleep disturbance, fatigue, pain/myotonia, gastrointestinal dysfunction, 
central sensory impairment, and communication difﬁculties. Difﬁculty with ambula-
tion was the most frequently mentioned issue by our sample of patients. CONCLU-
SIONS: There are multiple themes and symptoms, some previously underrecognized, 
that play a key role in DM1 patient reported HRQOL. These issues must be carefully 
examined in order to develop a representative disease-speciﬁc conceptual model and 
PRO measurement tool. The development of such an instrument has the potential to 
improve DM1 clinical care and maximize the impact and relevance of future DM1 
clinical research.
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OBJECTIVES: The Rheumatoid Arthritis Quality of Life scale (RAQoL) is the ﬁrst 
true QoL measure for RA and is widely used in clinical practice and trials. The scale 
has good psychometric properties and has been shown to be responsive to changes in 
disease severity. The objective of the study was to adapt the RAQoL for USA, Mexico, 
